Amneal Pharmaceuticals(AMRX) - 2023 Q4 - Annual Results

Exhibit 99.1 1 AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS ‒ Full Year 2023 Performance Met or Exceeded Financial Guidance Metrics – ‒ Q4 2023 Net Revenue of $617 million; GAAP Net Loss of $99 million; Diluted Loss per Share of $0.40 ‒ ‒ Q4 2023 Adjusted Net Income of $44 million, Adjusted EBITDA of $142 million; Adjusted Diluted EPS of $0.14 ‒ (1) (1) (1) ‒ Full Year 2023 Net Revenue of $2.39 billion; GAAP Net Loss of $84 million; Diluted Loss per Share of $0.48 ‒ ‒ Full Year 2023 Ad ...